Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585231 · ClinicalTrials.gov registry record · NA
Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 404
- Enrollment target
NCT03585231: Completed NA study, sponsored by Fred Hutchinson Cancer Center.
NCT03585231 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 404 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03585231, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 404 participants
- Enrollment target
Study Summary
Conversational agents (CAs) are computer-powered digital coaches designed to form long-term social-emotional connections with users through conversations. We have developed a CA for cigarette smoking cessation. In a pilot randomized trial (N = 415), we will compare the experimental messaging program (n = 155) with the standard of care national government smoking cessation messaging program (n = 157), and then we will compare immediate (n=51) versus delayed (n=51) access to the the experimental messaging program, to assess 12-week usability, receptivity, and preliminary cessation results in adults in western Washington State and nationally across the US who want to quit smoking.
Primary Outcome
No smoking in the past 30 days, as reported 3 month post treatment.
Interventions
- BEHAVIORAL Immediate access to novel messaging program intervention
- BEHAVIORAL Immediate access to standard of care messaging program intervention
- BEHAVIORAL Delayed access to novel novel messaging program intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2020-12-02 |
| Phase | NA |
What the finished NCT03585231 record still lists
NCT03585231 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 3 interventions - of which Immediate access to novel messaging program intervention is the first listed.
NCT03585231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03585231 about?
NCT03585231 is a clinical study titled "Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)". Conversational agents (CAs) are computer-powered digital coaches designed to form long-term social-emotional connections with users through conversations. We have developed a CA for cigarette smoking cessation. In a pilot randomized trial (N = 415), we will compare the experimental messaging program...
What is the current status of trial NCT03585231?
This trial is currently completed. It is a NA study. The enrollment target is 404 participants. The study started on 2018-09-17. Estimated completion is 2020-12-02.
What interventions are being tested in trial NCT03585231?
The interventions under investigation include: Immediate access to novel messaging program intervention (BEHAVIORAL), Immediate access to standard of care messaging program intervention (BEHAVIORAL), Delayed access to novel novel messaging program intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03585231?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03585231's enrollment target sits among peer trials
404 244th of 2000 higher than 1,757 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI